88 research outputs found
ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial
Background: ACE inhibition results in secondary prevention of coronary artery disease (CAD) through different mechanisms including improvement of endothelial dysfunction. The Perindopril-Function of the Endothelium in Coronary artery disease Trial (PERFECT) evaluated whether long-term administration of perindopril improves endothelial dysfunction.
Methods: PERFECT is a 3-year double blind randomised placebo controlled trial to determine the effect of perindopril 8 mg once daily on brachial artery endothelial function in patients with stable CAD without clinical heart failure. Endothelial function in response to ischaemia was assessed using ultrasound. Primary endpoint was difference in flow-mediated vasodilatation (FMD) assessed at 36 months.
Results: In 20 centers, 333 patients randomly received perindopril or matching placebo. Ischemia-induced FMD was 2.7% (SD 2.6). In the perindopril group FMD went from 2.6% at baseline to 3.3% at 36 months and in the placebo group from 2.8 to 3.0%. Change in FMD after 36 month treatment was 0.55% (95% confidence interval −0.36, 1.47; p = 0.23) higher in perindopril than in placebo group. The rate of change in FMD per 6 months was 0.14% (SE 0.05, p = 0.02) in perindopril and 0.02% (SE 0.05, p = 0.74) in placebo group (0.12% difference in rate of change p = 0.07).
Conclusion: Perindopril resulted in a modest, albeit not statistically significant, improvement in FMD
Oxprenolol in Myocardial Infarction Survivors: Brief Review of the European Infarction Study Results in the Light of Other Beta-Blocker Post Infarction Trials
The prognostic significance of angina pectoris experienced during the first month following acute myocardial infarction
Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury
Subgroups, treatment effects, and baseline risks: Some lessons from major cardiovascular trials
Anistreplase (Anisoylated Plasminogen Streptokinase Activator Complex, Apsac) in Coronary Thrombolysis
Beta Adrenoreceptor Blocking Drugs in Patients who have Suffered Acute Myocardial Infarction
- …